Table 2.

Clinical and Demographic Characteristics of Included Trials

Variable	Trial Result		p-value+
	Positive	Negative
	(ES<0)	(ES>0)
	N=45	N=15
Trial Duration (weeks)	11.8 (9.9)	14.8 (11.2)	0.06
Sample size (anti-inflammatory group)	30 (18)	52 (40)	0.09
Age (years)	38.7 (9.5)	37.8 (9.1)	0.75
Sex (% male)	46.7 (31.0)	65.6 (22.4)	0.02
Smoking (% yes)	55.6 (18.2)	N/A
BMI	26.5 (4.0)	28.4 (0.8)	0.28
Illness duration (years)	14.9 (10.1)	12.1 (9.8)	0.54
Age of Onset (years)	24.6 (3.5)	24.4 (4.1)	0.88
PANSS Total	80.7 (17.5)	76.1 (14.6)	0.38
PANSS Positive	19.8 (5.6)	19.9 (3.9)	0.83
PANSS Negative	21.0 (5.2)	22.1 (4.0)	0.59
PANSS General	40.4 (9.9)	42.6 (4.9)	0.56
Study Quality Score	4.9 (1.4)	3.9 (1.2)	0.03
	n (%)	n (%)
Geography			0.44
Middle East	15 (33.3)	4 (26.7)
Europe	9 (20.0)	2 (13.3)
United States	6 (13.3)	5 (11.1)
Australia	9 (20.0)	1 (6.7)
Asia	5 (11.1)	2 (13.3)
South Africa	1 (2.2)	1 (6.7)

Selected sociodemographic and clinical characteristics of included trials, stratified based on whether the overall effect size favored anti-inflammatory (ES<0) or placebo (ES>0).